Cargando…

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda

The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumakech, Edward, Berggren, Vanja, Wabinga, Henry, Lillsunde-Larsson, Gabriella, Helenius, Gisela, Kaliff, Malin, Karlsson, Mats, Kirimunda, Samuel, Musubika, Caroline, Andersson, Sören
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970808/ https://www.ncbi.nlm.nih.gov/pubmed/27482705 http://dx.doi.org/10.1371/journal.pone.0160099

Ejemplares similares

Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study
por: Kumakech, Edward, et al.
Publicado: (2017)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

HPV16 viral characteristics in primary, recurrent and metastatic vulvar carcinoma
por: Lillsunde Larsson, Gabriella, et al.
Publicado: (2018)

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
por: Kavanagh, K, et al.
Publicado: (2014)

HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign
por: Batmunkh, Tsetsegsaikhan, et al.
Publicado: (2019)

Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study
por: Mesher, David, et al.
Publicado: (2016)

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
por: Kreimer, Aimée R., et al.
Publicado: (2011)

Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
por: Yao, Xingmei, et al.
Publicado: (2022)

Comparison of the Immune Responses to Different Formulations of BC02-Adjuvanted HPV Types 16 and 18 Bivalent Vaccines in Mice
por: Li, Junli, et al.
Publicado: (2023)

Digital droplet PCR (ddPCR) for the detection and quantification of HPV 16, 18, 33 and 45 - a short report
por: Lillsunde Larsson, Gabriella, et al.
Publicado: (2017)

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand
por: Jiamsiri, Suchada, et al.
Publicado: (2022)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens
por: Arribillaga, Laura, et al.
Publicado: (2020)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali
por: Téguété, Ibrahima, et al.
Publicado: (2017)

In silico design of a multi-epitope vaccine against HPV16/18
por: Sanami, Samira, et al.
Publicado: (2022)

A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
por: Yin, Fei, et al.
Publicado: (2017)

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
por: Wacholder, Sholom, et al.
Publicado: (2010)

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
por: Diaz, M, et al.
Publicado: (2008)

Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
por: Vu, Lan TH, et al.
Publicado: (2013)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Reduction in HPV 16/18 prevalence among young women following HPV vaccine introduction in a highly vaccinated district, Japan, 2008–2017
por: Karube, Akihiro, et al.
Publicado: (2019)

Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China
por: Zhang, Qian, et al.
Publicado: (2016)

Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
por: Wan, Bing, et al.
Publicado: (2022)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial
por: Tsang, Sabrina H., et al.
Publicado: (2022)

Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina
por: González, Joaquín Víctor, et al.
Publicado: (2020)

Development of HPV(16,18,31,45) E5 and E7 peptides-based vaccines predicted by immunoinformatics tools
por: Namvar, Ali, et al.
Publicado: (2020)

Declining Genital Warts in Young Women in England Associated With HPV 16/18 Vaccination: An Ecological Study
por: Howell-Jones, Rebecca, et al.
Publicado: (2013)

Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods
por: Tîrziu, Alexandru, et al.
Publicado: (2023)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study
por: Kurokawa, Tetsuji, et al.
Publicado: (2020)

Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program
por: Matsumoto, Koji, et al.
Publicado: (2019)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bfge37g1l4td44nnpidrskij2p